Newsletter | August 19, 2026

08.19.26 -- Why Ending Rh Disease Requires More Than A Breakthrough (Part 3 of 3)

Welcome to the Drug Discovery Online newsletter, delivering weekly updates on the latest developments in drug discovery and early-stage development. Based on your professional interests, we believe you’ll find it useful for staying informed on emerging technologies and scientific advances, identifying new approaches to discovery and preclinical research, and connecting with potential partners and solution providers.


If not, you can unsubscribe at any time.



SPONSOR

The World Patient Safety Congress Americas (formerly known as World Drug Safety Congress Americas) returns to the Thomas M.Menino Convention & Exhibition Center, Boston from October 13-15, 2026. This premier event brings together over 1,800 leaders from pharma, biotech, and regulatory bodies to explore the future of pharmacovigilance. With a focus on AI, automation, and patient-centricity, the congress provides a vital platform for industry experts to share innovative strategies and ensure safety excellence across pharmaceutical drugs and medical devices.

FEATURED EDITORIAL

Why Ending Rh Disease Requires More Than A Breakthrough (Part 3 of 3)

Rh disease has been preventable for decades. Yet babies still die worldwide because access, supply, and infrastructure have not caught up.

Early Decisions That Shape Success In CNS Drug Development And Commercialization, Part 2

In part 2, Ginger continues to provide insights for R&D teams on CNS development and commercialization.

Oncology Drug Discovery Is Targeting The Wrong Problem

There is a growing tension between what we measure and what ultimately matters. This disconnect raises an uncomfortable but necessary question: are we targeting the right problem?

INDUSTRY INSIGHTS

Methodologies To Characterize Bioavailability Enhancing Formulations

Formulators have many choices when it comes to bioavailability enhancement. Which should you use for a given compound? Explore tools to predict the performance of bioavailability-enhanced formulations.

Diagnose Absorption Risks To Improve Preclinical And Clinical Outcomes

Physiologically based pharmacokinetic modeling is a powerful tool for clinical trial design that can be leveraged alongside early development experiments to reduce costs and accelerate timelines.

Residual DNA Testing Across Biotherapeutics

Residual host cell DNA testing can create bottlenecks. Learn how digital PCR supports more consistent quantification, simpler method deployment, and faster in-process and lot release decisions.

Automated Library Prep For A Nanopore DNA Barcoding Protocol

A streamlined workflow reduces reagent use and hands‑on time while preserving long‑read sequencing quality. See how multiplexed offer an efficient option for scaling or mobilizing sequencing efforts.

Fluorochrome And Laser Reference Guide

Match fluorochromes with lasers for precise flow cytometry. Uncover brightness levels, antigen pairing recommendations, and tips to reduce nonspecific binding for optimal panel design and reliable results.

Discovery, Characterization Of Epitope-Diverse MMR Protein Antibodies

Gain insight into how these high-affinity, epitope-diverse mAbs provide a powerful toolkit to dissect the role of DNA mismatch repair (MMR) proteins in HD.

SOLUTIONS

NMR Software For Data Analysis And Structure Verification

A Human-Relevant Liver Model With Minimal Drug Absorption